Waiv Raises $33M to Scale AI-Powered Cancer Precision Testing Platform Globally
核心洞察
Waiv (搜索), a Paris-based startup spun out from biotech unicorn Owkin (搜索), secured $33 million in funding co-led by OTB Ventures (搜索) and Alpha Intelligence Capital (搜索) to expand its AI-driven precision testing platform for cancer care.
The company's platform transforms routine clinical and histopathology data into ready-to-use precision tests, delivering results in minutes through tools like RlapsRisk BC (搜索), MSIntuit Suite (搜索), and BRCAura (搜索) without requiring labs to overhaul existing systems.
Waiv (搜索) works with pharmaceutical companies to accelerate drug development through AI-powered biomarker detection and patient stratification, including collaborations with MSD for MSI (搜索)-enriched group identification.
Waiv (搜索), a Paris-based medical testing startup spun out from biotech unicorn Owkin (搜索), has raised $33 million in Series A funding to accelerate global expansion of its AI-powered precision testing platform for cancer care. The round was co-led by OTB Ventures (搜索) and Alpha Intelligence Capital (搜索), with participation from Serena Data Ventures, Karista, and SistaFund.
The company, founded by Owkin (搜索) alumni Meriem Sefta and Lionel Guillou, leverages ten years of AI research from its parent company to transform routine clinical and histopathology data into actionable precision tests. Waiv (搜索)'s platform addresses the growing complexity of cancer care, where patients present with multiple biomarkers requiring integration of biological, genomic, and clinical data for optimal treatment decisions.
AI-Driven Testing Platform Delivers Rapid Results
Waiv (搜索)'s technology platform delivers precision testing results in minutes through tools including RlapsRisk BC (搜索), MSIntuit Suite (搜索), and BRCAura (搜索). The system enables rapid patient stratification and accelerated treatment decision-making without requiring laboratories to overhaul existing IT infrastructure.
"Precision medicine only works when patients can be reliably matched to the therapies most likely to benefit them. This remains very complex to achieve," said CEO Meriem Sefta. "Our goal is to make accurate AI-enabled precision testing the global standard."
The platform integrates proprietary AI models, multimodal analytics, and data from the PortrAIt consortium, described as one of Europe's largest multi-institutional precision medicine datasets. The company's Destra platform seamlessly integrates with existing laboratory systems, enabling deployment of AI-powered tests without major IT infrastructure changes.
Pharmaceutical Partnerships Drive Drug Development
Waiv (搜索) has established collaborations with leading pharmaceutical companies to accelerate drug development processes. Notable partnerships include BRCAura (搜索) for AI-powered gBRCA (搜索) pre-screening and a collaboration with MSD to identify MSI (搜索)-enriched patient groups. These partnerships enhance clinical trial efficiency and improve patient-treatment matching for personalized medicine applications.
Fabrice André from Gustave Roussy (搜索) noted that tools like RlapsRisk BC (搜索) are now reaching more patients than ever, delivering measurable improvements in both clinical outcomes and operational efficiency. The platform automates compliance checks and validation processes, allowing laboratory staff to focus on critical decision-making tasks.
Transforming Traditional Diagnostic Workflows
Traditional cancer diagnostics struggle to integrate multiple data sources including histopathology slides, patient records, and biomarker results, creating bottlenecks that limit precision medicine implementation. Waiv (搜索)'s platform addresses these limitations by converting routine laboratory data into ready-to-use AI tests for clinical settings.
The system provides rapid analysis of genetic markers such as gBRCA (搜索) mutations and MSI (搜索) markers without requiring next-generation sequencing. This approach enables laboratories to scale AI-powered testing operations while maintaining accuracy through continuous clinical validation and comprehensive audit trails.
"Waiv (搜索) is bringing a level of technological advancement and maturity that oncology has been waiting for," said Karol Szubstarski, partner at OTB Ventures (搜索). "We are excited to partner with a world-class team and support Waiv as they set a new standard for how oncology is understood and treated."
Global Expansion and Dataset Diversification
The $33 million funding will support expansion of Waiv (搜索)'s clinical-grade test portfolio, deeper pharmaceutical partnerships, and international market penetration. The company plans to enhance the PortrAIt consortium to ensure datasets reflect global diversity, improving AI model performance across different patient populations.
Arnaud Barthélémy from Alpha Intelligence Capital (搜索) highlighted that Waiv (搜索)'s AI platform scales effectively while improving laboratory capabilities for outcome prediction and biomarker detection, delivering measurable clinical impact worldwide.
The platform supports both diagnostic applications and biomarker discovery while facilitating clinical trial readiness for personalized therapy development. By integrating AI, pathology, and advanced analytics, Waiv (搜索) enables enhanced collaboration between pharmaceutical companies and healthcare providers, allowing laboratories to implement advanced precision testing at scale while providing patients with faster, more personalized treatment options.